366 related articles for article (PubMed ID: 26028030)
1. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
[TBL] [Abstract][Full Text] [Related]
2. DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion.
Niu J; Shi Y; Tan G; Yang CH; Fan M; Pfeffer LM; Wu ZH
J Biol Chem; 2012 Jun; 287(26):21783-95. PubMed ID: 22547075
[TBL] [Abstract][Full Text] [Related]
3. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
4. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
5. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
6. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.
Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q
Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124
[TBL] [Abstract][Full Text] [Related]
7. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
[TBL] [Abstract][Full Text] [Related]
8. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
9. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
11. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
Wang PS; Chou CH; Lin CH; Yao YC; Cheng HC; Li HY; Chuang YC; Yang CN; Ger LP; Chen YC; Lin FC; Shen TL; Hsiao M; Lu PJ
Oncogene; 2018 Aug; 37(34):4662-4678. PubMed ID: 29755127
[TBL] [Abstract][Full Text] [Related]
12. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
13. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-181a suppresses salivary adenoid cystic carcinoma metastasis by targeting MAPK-Snai2 pathway.
He Q; Zhou X; Li S; Jin Y; Chen Z; Chen D; Cai Y; Liu Z; Zhao T; Wang A
Biochim Biophys Acta; 2013 Nov; 1830(11):5258-66. PubMed ID: 23911747
[TBL] [Abstract][Full Text] [Related]
15. Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor-
Wang W; Zhang B; Mani AM; Wu Z; Fan Y; Li W; Wu ZH
J Pharmacol Exp Ther; 2018 Jul; 366(1):184-193. PubMed ID: 29735611
[TBL] [Abstract][Full Text] [Related]
16. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.
Xu X; Zhang Y; Jasper J; Lykken E; Alexander PB; Markowitz GJ; McDonnell DP; Li QJ; Wang XF
Oncotarget; 2016 Apr; 7(15):20381-94. PubMed ID: 26967387
[TBL] [Abstract][Full Text] [Related]
17. The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells.
Zhu Y; Wu J; Li S; Ma R; Cao H; Ji M; Jing C; Tang J
Cell Physiol Biochem; 2013; 32(5):1225-37. PubMed ID: 24335172
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
20. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
